ClinicalTrials.gg
CompletedNCT03001700PRELUDEUpdated Apr 24, 2018

PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE

An interventional study of Serranator™ Alto PTA Serration Balloon Catheter in Peripheral Arterial Disease, sponsored by Cagent Vascular LLC. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-24.

Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was May 2017, 9 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.

Enrollment
26th of 28
25 · median 220
Started
2017
with 1 other
No phase
16 of 31
4 open now
Registered
14th of 31
by date
Lead sponsor
2 of 31
Cagent Vascular LLC

Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 26th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2017, is one of 16 with no phase, and was the 14th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Peripheral Arterial Disease with a site in Poland, or all of them as a file.
02

Study summary

To assess preliminary safety and efficacy of the Serranator™ Alto PTA Serration Balloon Catheter in subjects with atherosclerotic peripheral artery disease of the superficial femoral and popliteal arteries.

Read the detailed description

Single Arm, prospective, OUS multi-center feasibility study enrolling up to 30 subjects with superficial femoral or popliteal lesions. The study will capture acute angiographic data to compare the pre- Serranator™ inflation vs post inflation effects.

The study population will consist of subjects with claudication or ischemic rest pain, with de novo or non-stented restenotic lesions in femoropopliteal arteries having lesion length less than or equal to 10 cm, total occlusion up to 6 cms in length and reference vessel diameter of 4 mm to 6 mm, inclusive.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female of >18 years old.
  2. Women of child bearing potential must have a negative pregnancy test within 7 days of index procedure.
  3. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and comply with all follow-up visits and has signed the consent form.
  4. Resting ABI -\< 0.9.
  5. Subject is eligible for standard surgical repair in target limb if necessary.
  6. Subject has Rutherford Clinical Category 2,3, or 4
  7. Estimated > 1 year.

Angiographic Inclusion Criteria:

  1. Lesion(s) located within the SFA and or popliteal arteries.
  2. Target lesion(s) has stenosis >70% by visual assessment.
  3. Reference vessel diameter is between 4.0mm and 6.0mm, inclusive.
  4. One long or multiple serial lesions that are up to 10 cms, (total occlusions up to 6cm) in length that can be covered by a single balloon.
  5. De-novo, or non-stented re-stenotic lesions
  6. At least one below the knee artery patent to the ankle.
  7. Successful treatment of iliac inflow stenosis to the target limb. Stenosis can be treated during the same procedure using standard angioplasty and or stenting but use of atherectomy is excluded. The inflow lesion(s) must be treated first, prior to consideration of treatment of the target lesion. Subject can be enrolled if the inflow lesion(s) are treated and results in \<30% residual stenosis and no evidence of embolization or significant complications.

Exclusion criteria

Exclusion Criteria:

  1. Rutherford Clinical Category 1, 5 or 6.
  2. Previously implanted ipsilateral femoral or popliteal stent.
  3. Evidence of aneurysm or acute thrombus in the target vessel.
  4. Subjects with previous bypass surgery in lower target extremity.
  5. Planned major amputation (above the ankle) of either limb.
  6. Subject has significant stenosis or occlusion of inflow tract not successfully treated (>30% residual stenosis and/or significant complication of the procedure).
  7. History of any open surgical procedure within the past 30 days.
  8. Planned endovascular or vascular surgery procedure within 14 days prior to the ATK procedure, except to treat the inflow vessels on the day of the procedure, or within the next 30 days after the ATK procedure on the target limb.
  9. Subject has an allergy to contrast medium that cannot be pretreated.
  10. Episode of acute limb ischemia within past 30 days.
  11. Subject has systemic infection with positive blood cultures/ bacteremia within one week.
  12. Subject has a hypercoagulable disorder
  13. Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is .
  14. Myocardial infarction within 30 days prior to enrollment.
  15. History of stroke or within 90 days prior to enrollment.
  16. Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L).
  17. Subject is pregnant or breastfeeding.
  18. Subject is participating in another research study of a device, medication, which could, in the opinion of the investigator, affect the results of this study.
  19. Subject has other medical, social or psychological problems that in the opinion of the investigator would preclude them from receiving this treatment and the procedures and or participating in evaluations pre- and post-treatment.
  20. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.
  21. Known allergies to both antiplatelet agents, aspirin, or heparin.
  22. History of neutropenia, coagulopathy, or thrombocytopenia that was unexplained or is considered to be at risk for reoccurrence.
  23. count less than 80,000/μL,
  24. Subject requires general anesthesia for the procedure.
  25. Subject requires dialysis.

Angiographic Exclusion Criteria:

  1. Chronic Total Occlusions (CTO) > 6cm in length
  2. Acute Total Occlusions; evidence of acute thrombus formation by angiography
  3. Severe calcification of target lesion described as circumferential calcium and >50% of lesion length.
  4. Sub-intimal access required
  5. Inability to cross the lesion with a guidewire
  6. Atherectomy in the target lesion, target artery or for inflow treatment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Treatment

    Subjects will be treated with the Serranator™ Alto PTA Serration Balloon Catheter device

    Device: Serranator™ Alto PTA Serration Balloon Catheter

Interventions

  • DeviceSerranator™ Alto PTA Serration Balloon Catheter

    The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.

06

What researchers measure

Primary outcomes

  1. To evaluate the technical feasibility of using the Serranator™ Alto PTA Serration Balloon Catheter during the endovascular treatment of critical SFA or popliteal artery lesions.

    Time frame: Through Study Completion, approximately 6 months

Secondary outcomes

  1. OCT and/or IVUS imaging post use of the Serranator to document evidence of vessel wall serrations in a sub-set of up to 10 subjects.

    Time frame: Through Study Completion, approximately 6 months

07

Study locations

4 sites
  • Medizinische Universtität Graz
    Graz, A-8036, Austria
  • Auckland City Hospital
    Auckland, Grafton 1023, New Zealand
  • Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo Naczyniowe
    Chrzanow, 32-050, Poland
  • Szpital Uniwersytecki w Krakowie Pracownia Angiografii Oddział Angiologii
    Krakow, 31-066, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2017, 3 months.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 3 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2016
First posted
Dec 23, 2016
StartActual
Feb 1, 2017
Primary completionActual
May 31, 2017
CompletionActual
Dec 31, 2017
Last update
Apr 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03001700
Lead sponsor
Cagent Vascular LLC
Responsible party
Sponsor
First posted
Dec 23, 2016
Start date
Feb 1, 2017
Primary completion
May 31, 2017
Completion
Dec 31, 2017
Last update
Apr 24, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion